

Jeffrey A Jones

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2182566/publications.pdf>

Version: 2024-02-01

104
papers

7,246
citations

159585

30
h-index

54911

84
g-index

104
all docs

104
docs citations

104
times ranked

7234
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2013, 369, 32-42.	27.0	2,019
2	Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. <i>Blood</i> , 2015, 125, 2497-2506.	1.4	618
3	Phosphatidylinositol 3-kinase- γ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. <i>Blood</i> , 2010, 116, 2078-2088.	1.4	523
4	Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , 2015, 1, 80.	7.1	498
5	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 48-58.	10.7	438
6	Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. <i>Lancet Oncology</i> , The, 2016, 17, 1409-1418.	10.7	290
7	Ibrutinib treatment improves T cell number and function in CLL patients. <i>Journal of Clinical Investigation</i> , 2017, 127, 3052-3064.	8.2	280
8	Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease. <i>Journal of Clinical Oncology</i> , 2009, 27, 6012-6018.	1.6	212
9	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017, 129, 553-560.	1.4	193
10	Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. <i>Lancet Haematology</i> , the, 2017, 4, e114-e126.	4.6	181
11	Ventricular arrhythmias and sudden death in patients taking ibrutinib. <i>Blood</i> , 2017, 129, 2581-2584.	1.4	161
12	Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. <i>Blood Advances</i> , 2017, 1, 1739-1748.	5.2	123
13	Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals. <i>Cancer Cell</i> , 2012, 21, 694-708.	16.8	122
14	Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. <i>Blood</i> , 2018, 131, 1704-1711.	1.4	122
15	High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2016, 128, 2931-2940.	1.4	102
16	ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. <i>Blood</i> , 2012, 120, 1262-1273.	1.4	91
17	Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 568-574.	0.4	72
18	Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 3626-3637.	1.6	71

#	ARTICLE	IF	CITATIONS
19	In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies. <i>Cancer</i> , 2008, 112, 1096-1105.	4.1	63
20	Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. <i>British Journal of Haematology</i> , 2017, 178, 286-291.	2.5	55
21	A single-institution retrospective cohort study of first-line R ² -EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. <i>British Journal of Haematology</i> , 2018, 180, 259-266.	2.5	53
22	Blue light flexible cystoscopy with hexaminolevulinat in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA – update 2018. <i>Nature Reviews Urology</i> , 2019, 16, 377-386.	3.8	51
23	Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. <i>Lancet Haematology</i> , 2019, 6, e366-e374.	4.6	49
24	Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. <i>Blood</i> , 2016, 128, 637-637.	1.4	48
25	Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 1649-1657.	1.3	42
26	Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 4322-4327.	7.1	38
27	Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. <i>MAbs</i> , 2014, 6, 748-754.	5.2	37
28	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. <i>British Journal of Haematology</i> , 2018, 182, 504-512.	2.5	37
29	Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias. <i>JAMA Oncology</i> , 2015, 1, 684.	7.1	35
30	Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE-17 Trial. <i>Blood</i> , 2014, 124, 327-327.	1.4	33
31	A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy. <i>Annals of Hematology</i> , 2016, 95, 1137-1143.	1.8	31
32	Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 1008-1011.	1.3	29
33	Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib. <i>Blood Advances</i> , 2019, 3, 116-118.	5.2	28
34	Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center. <i>Blood</i> , 2017, 130, 830-830.	1.4	27
35	Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 19-24.	4.1	26
36	Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy. <i>Blood</i> , 2015, 126, 715-715.	1.4	26

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study. <i>Blood</i> , 2016, 128, 1215-1215.	1.4	25
38	ERR1- and PGC1 α -associated mitochondrial alterations correlate with pan-cancer disparity in African Americans. <i>Journal of Clinical Investigation</i> , 2019, 129, 2351-2356.	8.2	24
39	Phase 1b Results of a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016, 128, 639-639.	1.4	22
40	OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. <i>Blood</i> , 2015, 125, 284-295.	1.4	19
41	Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 278-285.e1.	0.4	19
42	Individual differences in physical symptom burden and psychological responses in individuals with chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2016, 95, 1989-1997.	1.8	19
43	Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. <i>Haematologica</i> , 2012, 97, 423-427.	3.5	17
44	Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells. <i>Cancer Immunology Research</i> , 2016, 4, 698-707.	3.4	15
45	The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia. <i>Cancer Medicine</i> , 2017, 6, 778-787.	2.8	15
46	Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study. <i>Blood</i> , 2015, 126, 833-833.	1.4	15
47	Choosing first-line therapy for chronic lymphocytic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1379-1390.	2.4	14
48	A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2212-2215.	1.3	13
49	Space Radiation Protection Countermeasures in Microgravity and Planetary Exploration. <i>Life</i> , 2021, 11, 829.	2.4	13
50	Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. <i>Leukemia and Lymphoma</i> , 2019, 60, 1438-1446.	1.3	12
51	Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATE TM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2014, 124, 4696-4696.	1.4	12
52	A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2014, 38, 1025-1029.	0.8	11
53	Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013, 122, 871-871.	1.4	11
54	Biologically-Based and Physiochemical Life Support and In Situ Resource Utilization for Exploration of the Solar System—Reviewing the Current State and Defining Future Development Needs. <i>Life</i> , 2021, 11, 844.	2.4	10

#	ARTICLE	IF	CITATIONS
55	Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy. <i>Blood</i> , 2014, 124, 1990-1990.	1.4	10
56	A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2951-2951.	1.4	10
57	Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101. <i>Leukemia and Lymphoma</i> , 2013, 54, 2654-2659.	1.3	9
58	Sixty-minute infusion rituximab protocol allows for safe and efficient workflow. <i>Supportive Care in Cancer</i> , 2016, 24, 1125-1129.	2.2	9
59	Jumping translocations, a novel finding in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015, 170, 200-207.	2.5	8
60	BRAF V600E expression in histiocytic sarcoma associated with splenic marginal zone lymphoma: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 92.	0.8	8
61	Major Bleeding Complications Among Patients Treated with Ibrutinib and Concomitant Antiplatelet, Anticoagulant, or Supplemental Therapy. <i>Blood</i> , 2016, 128, 4387-4387.	1.4	8
62	the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL. <i>Blood</i> , 2016, 128, 55-55.	1.4	8
63	Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective. <i>Haematologica</i> , 2015, 100, e18-e20.	3.5	7
64	Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism. <i>Blood</i> , 2016, 128, 3238-3238.	1.4	5
65	Low Incidence of Opportunistic Infections in CLL Patients Treated with Single Agent Flavopiridol.. <i>Blood</i> , 2007, 110, 3128-3128.	1.4	5
66	CAL-101, a Selective Inhibitor of the p110 β Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease. <i>Blood</i> , 2008, 112, 3165-3165.	1.4	4
67	Repair-Assisted Damage Detection Reveals Biological Disparities in Prostate Cancer between African Americans and European Americans. <i>Cancers</i> , 2022, 14, 1012.	3.7	4
68	Lipid Alterations in African American Men with Prostate Cancer. <i>Metabolites</i> , 2022, 12, 8.	2.9	4
69	Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 6187-6195.	7.0	3
70	Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).. <i>Blood</i> , 2007, 110, 3104-3104.	1.4	3
71	a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2016, 128, 1776-1776.	1.4	3
72	Leukemic Cell Expressed CTLA-4 Suppresses T Cells Via Down-Modulation of CD80 By Trans-Endocytosis. <i>Blood</i> , 2016, 128, 3221-3221.	1.4	3

#	ARTICLE	IF	CITATIONS
73	Temporal Profiles of Lymphocyte Subsets and the Correlation with Infectious Events in Idelalisib-Treated Patients. <i>Blood</i> , 2016, 128, 5583-5583.	1.4	3
74	Trametinib for the Treatment of IGHV4-34, MAP2K1 Mutant Variant Hairy Cell Leukemia. <i>Blood</i> , 2016, 128, 5598-5598.	1.4	3
75	Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells. <i>Blood</i> , 2012, 120, 775-775.	1.4	2
76	B-1239, a Novel Anti-BAFF-R Afucosylated Human Antibody, Promotes Potent Natural Killer Cell-Mediated Antibody Dependent Cellular Cytotoxicity In Chronic Lymphocytic Leukemia Cells In- Vitro and Depletion Of Circulating Leukemic CLL B Cells In-Vivo. <i>Blood</i> , 2013, 122, 4185-4185.	1.4	2
77	A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 2953-2953.	1.4	2
78	Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center. <i>Blood</i> , 2016, 128, 2040-2040.	1.4	2
79	Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL. <i>Blood</i> , 2016, 128, 4385-4385.	1.4	2
80	Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones. <i>Blood</i> , 2016, 128, 4386-4386.	1.4	2
81	A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features. <i>Blood</i> , 2016, 128, 4388-4388.	1.4	2
82	A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,. <i>Blood</i> , 2011, 118, 3912-3912.	1.4	2
83	del(17p13.1) in Chronic Lymphocytic Leukemia Confers Poor Prognosis Even at Low Percentage Involvement and Increases Proportionately with Increase in Clonal Involvement.. <i>Blood</i> , 2007, 110, 2073-2073.	1.4	1
84	A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin's Lymphoma. <i>Blood</i> , 2008, 112, 3053-3053.	1.4	1
85	In-Hospital Mortality and Trends Associated with Splenectomy in Patients with Immune-Mediated Thrombocytopenia (ITP).. <i>Blood</i> , 2009, 114, 1398-1398.	1.4	1
86	Weight gain after lymphoma treatment: fat or fiction?. <i>Leukemia and Lymphoma</i> , 2012, 53, 517-518.	1.3	0
87	Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2008, 112, 3300-3300.	1.4	0
88	A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation. <i>Blood</i> , 2008, 112, 3169-3169.	1.4	0
89	Flavopiridol Treatment of Patients Aged 70 or Older with Refractory or Relapsed Chronic Lymphocytic Leukemia Is Feasible and Not Associated with Adverse Outcome When Compared to Younger Patients. <i>Blood</i> , 2010, 116, 1378-1378.	1.4	0
90	The Prognostic Value of FDG PET/CT Prior to Autologous Stem Cell Transplant in Mantle Cell Lymphoma. <i>Blood</i> , 2011, 118, 3113-3113.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials.. Blood, 2011, 118, 1791-1791.	1.4	0
92	Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial,. Blood, 2011, 118, 3910-3910.	1.4	0
93	Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals. Blood, 2011, 118, 622-622.	1.4	0
94	Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma,. Blood, 2011, 118, 3707-3707.	1.4	0
95	Lymphocyte Cytosolic Protein 1 (LCP1) Is a Membrane Associated Molecular Target in Chronic Lymphocytic Leukemia and Is Activated in Microenvironment Signaling. Blood, 2012, 120, 3866-3866.	1.4	0
96	Identification of Endoplasmic Reticulum Stress Inducing Agents by Antagonizing Autophagy: A New Potential Strategy for Identification of Anti-Cancer Therapeutics in B-Cell Malignancies.. Blood, 2012, 120, 2473-2473.	1.4	0
97	Fatigue, Distress, and Quality of Life As Covariates for Early-Stage Chronic Lymphocytic Leukemia. Blood, 2012, 120, 2075-2075.	1.4	0
98	A Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). Blood, 2012, 120, 1800-1800.	1.4	0
99	The Hsp90 Inhibitor 17-DMAG Increases SOCS3 and Regulates Cytokine Production, Migration and Cell Death in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 1362-1362.	1.4	0
100	Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype. Blood, 2013, 122, 2872-2872.	1.4	0
101	A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and In Vi tro Potency in B-Cell Malignancies. Blood, 2015, 126, 318-318.	1.4	0
102	Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. Blood, 2016, 128, 3198-3198.	1.4	0
103	A Distributed International Patient Data Registry for Hairy Cell Leukemia. Blood, 2016, 128, 5986-5986.	1.4	0
104	BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma. Blood, 2016, 128, 2767-2767.	1.4	0